Liver cirrhosis is a chronic liver disease marked by irreversible scarring of liver tissue, often resulting from hepatitis, alcohol abuse, or nonalcoholic fatty liver disease. It accounts for around 1.16 million deaths annually, with liver cancer contributing significantly to this toll. The development of liver cirrhosis therapeutics is gaining momentum, driven by a growing focus on targeted therapies, anti-fibrotic agents, and regenerative medicine. According to the liver cirrhosis pipeline analysis by Expert Market Research, advancements in drug discovery and increasing R&D investments are expected to fuel the growth of liver cirrhosis therapeutic products in the coming years.
Major companies involved in the liver cirrhosis pipeline analysis include Madrigal Pharmaceuticals, Inc., AstraZeneca, and others.
Leading drugs currently in the pipeline include AZD2389, PHIN-214, and others.
The pipeline for liver cirrhosis is expanding, driven by rising NASH-related cirrhosis cases, increasing clinical trials for antifibrotic agents, and growing investment in regenerative and cell-based therapies.
The Liver Cirrhosis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into liver cirrhosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for liver cirrhosis. The liver cirrhosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The liver cirrhosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with liver cirrhosis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to liver cirrhosis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Liver cirrhosis is a chronic, progressive condition marked by irreversible scarring of the liver due to long-term liver damage. It typically results from prolonged inflammation caused by alcohol abuse, viral hepatitis, or metabolic disorders like MASH (Metabolic Dysfunction-Associated Steatohepatitis). Over time, healthy liver tissue is replaced by fibrotic tissue, impairing liver function.
Liver cirrhosis treatment focuses on managing symptoms, slowing disease progression, and preventing related complications. Treatment options include antiviral therapy, lifestyle changes, medications, and in severe cases, liver transplantation. In May 2024, the U.S. Food and Drug Administration approved resmetirom as a promising treatment for MASH-related fibrosis. This drug, combined with lifestyle modification, offers a targeted approach to slow progression toward cirrhosis.
According to Silvia Cagnin et al., 2024, liver cirrhosis remains a critical global health challenge, with 1.16 million deaths annually. It contributes to 3.5% of global mortality. Chronic liver disease ranks among the top 20 causes of death worldwide. According to the World Health Organization, approximately 75% of liver cirrhosis cases result from hepatitis B and C infections. In 2022, 70.5 million individuals in the South-East Asia Region lived with viral hepatitis. Timely diagnosis and treatment can significantly reduce future liver cancer-related deaths in the region.
This section of the report covers the analysis of liver cirrhosis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total liver cirrhosis clinical trials, at 38%. It is followed by phase III at 31%, phase IV at 15%, and phase I at 14%. This robust clinical pipeline reflects strong research momentum, promising enhanced therapeutic options, and driving future growth in the liver cirrhosis market through advanced treatment developments.
The drug molecule categories covered under the liver cirrhosis pipeline analysis include small molecules, biologics, cell-based therapies, and peptides. The liver cirrhosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for liver cirrhosis. Anti-SIRPα agents are emerging as a promising drug class in the treatment pipeline for liver cirrhosis. For instance, BI 770371, developed by Boehringer Ingelheim (in collaboration with OSE Immunotherapeutics), is progressing from Phase I immuno-oncology studies to a Phase II trial. It targets liver cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH), and aims to modulate immune response and fibrosis progression.
The EMR report for the liver cirrhosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed liver cirrhosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in liver cirrhosis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for liver cirrhosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of liver cirrhosis drug candidates.
AZD2389, an oral small-molecule FAP inhibitor developed by AstraZeneca, is currently being evaluated in a Phase 2a clinical study to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in participants with liver fibrosis and compensated cirrhosis. This study is investigating how AZD2389 interacts with the body and its potential to regulate fibrosis by targeting fibroblast activation protein (FAP), which plays a key role in liver fibrogenesis during MASH.
PharmaIN is developing PHIN-214, a subcutaneous, once-daily terlipressin derivative for liver cirrhosis. The ongoing Phase 1 study is evaluating single and multiple ascending doses in Child-Pugh A and B cirrhotic patients. The objective is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of PHIN-214. It is showing promise in reducing portal hypertension and improving renal perfusion, with a broader therapeutic index than terlipressin. The drug works by partially activating V1a receptors, aiming to reduce splanchnic blood pooling and portal hypertension, thereby improving renal perfusion and systemic pressure.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Liver Cirrhosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for liver cirrhosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into liver cirrhosis collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share